<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073927</url>
  </required_header>
  <id_info>
    <org_study_id>H-18062027</org_study_id>
    <nct_id>NCT04073927</nct_id>
  </id_info>
  <brief_title>Effect of Butyrate on Inflammation and Albuminuria in Patients With Albuminuria, Type 1 Diabetes and Intestinal Inflammation</brief_title>
  <official_title>The Butyful Study. Effect of Butyrate on Inflammation and Albuminuria in Patients With Albuminuria, Type 1 Diabetes and Intestinal Inflammation A Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Folkhälsan Researech Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Steno Diabetes Center Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is to assess the impact of 12 weeks supplement of sodium-butyrate twice daily
      or placebo on intestinal inflammation and albuminuria.

      A randomized, placebo-controlled, double-blind, two-site trial including 48 patients with
      type 1 diabetes, albuminuria and intestinal inflammation. Participants will be randomized 1:1
      to active treatment or placebo for a period of 12 weeks.

      The primary endpoint is change from baseline to week 12 in intestinal inflammation, measured
      by fecal calprotectin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with type 1 diabetes, increased intestinal inflammation, reduced gut barrier
      function and resulting influx of proinflammatory molecules have been described. This might
      contribute to systemic inflammation and the development of diabetic complications like
      nephropathy and ischemic heart disease. Interestingly, the gut microbiota is altered in
      persons with type 1 diabetes, who have less butyrate-producing bacteria. The short-chain
      fatty acid butyrate improves the intestinal barrier function, and the altered bacterial
      composition is hypothesized to play a role in the intestinal inflammation. Treatment with
      butyrate has improved metabolic, colonic and renal function in animal models of chronic
      kidney disease.

      The aim of the study is to test whether orally ingested sodium butyrate can reduce intestinal
      inflammation in patients with type 1 diabetes and albuminuria in a randomized,
      placebo-controlled, double-blind, two-site trial.

      Persons with type 1 diabetes and albuminuria are recruited from Steno Diabetes Center
      Copenhagen (SDCC) and Folkhälsan Research Center, FinnDiane, Helsinki, Finland and screened
      for intestinal inflammation. 48 participants with intestinal inflammation (fecal calprotectin
      ≥50 μg/g) are randomized to receive 3.6 g sodium butyrate or placebo for 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2019</start_date>
  <completion_date type="Anticipated">August 5, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intestinal inflammation</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Change in concentration of fecal calprotectin determined by ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fecal intestinal alkaline phosphatase (IAP)</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Change in IAP activity in feces assessed by colorimetric assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short-chain fatty acids (SCFAs)</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Change in acetate, propionate, butyrate and valerate concentration in feces measured by gas chromatography-mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albuminuria</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Change in urinary albumin-creatinine ratio (UACR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kidney function</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Change in eGFR</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Albuminuria</condition>
  <arm_group>
    <arm_group_label>Sodium butyrate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3.6 g sodium butyrate. 6 capsules twice daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo. 6 capsules twice daily for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sodium butyrate</intervention_name>
    <description>Sodium butyrate Class: Fatty acids Ingredients (100 g): Na-butyrate (50 g), acylglycerol (mono- di, -triacylglycerol; 42 g), bee wax (5 g), sodium alginate E401 (2 g), emulsifier (0.5 g).
The capsules contain granulated sodium butyrate and are coated with a sodium alginate membrane.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Sodium butyrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients ≥ 18 years of age with a diagnosis of type 1 diabetes (age at
             onset &lt;40 years; permanent insulin treatment initiated within 1 year of diagnosis)

          2. Albuminuria: UACR &gt; 30 mg/g documented in medical history

          3. Calprotectin quick-test result ≥ 50 μg/g (CalDetect 50/200, Preventis) between visit 1
             and visit 2.

          4. Able to understand the written patient information and give informed consent

        Exclusion Criteria:

          1. Known inflammatory bowel disease

          2. IBD symptoms due to investigators opinion

          3. Known celiac disease

          4. Existing ostomy

          5. Known rheumatic disorders treated with anti-inflammatory agents

          6. Known hyperthyroidism or hypothyroidism Butyful Protocol - page 12 - Version 3,
             25.02.2019

          7. Active immunosuppressant therapy with systemic effect due to investigator's opinion

          8. Current cancer treatment or within five years from baseline (except basal cell skin
             cancer or squamous cell skin cancer)

          9. eGFR&lt;15, dialysis or kidney transplantation

         10. Diagnosis of non-diabetic CKD

         11. Active antibiotic therapy until 30 days ahead of screening

         12. Unable to participate in study procedures

         13. Not able to assess calprotectin by quick test in two attempts

         14. Any clinically significant disorder, except for conditions associated with type 1 DM
             history, which in the Investigators opinion could interfere with the results of the
             trial

         15. Pregnancy or lactation

         16. Participation in another intervention study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Rossing, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter Rossing, Professor</last_name>
    <phone>+45 30193383</phone>
    <email>peter.rossing@regionh.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ninna Hahn Tougaard, MD</last_name>
    <phone>+45 29399798</phone>
    <email>ninna.hahn.tougaard.01@regionh.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Steno Diabetes Center Copenhagen</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Rossing, Professor</last_name>
      <phone>+45 30193383</phone>
      <email>peter.rossing@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Folkhälsan Research Center, FinnDiane</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Markku Lehto</last_name>
      <phone>+358-40-7715484</phone>
      <email>markku.lehto@helsinki.fi</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 16, 2019</study_first_submitted>
  <study_first_submitted_qc>August 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>August 29, 2019</last_update_submitted>
  <last_update_submitted_qc>August 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Steno Diabetes Center Copenhagen</investigator_affiliation>
    <investigator_full_name>Peter Rossing</investigator_full_name>
    <investigator_title>Professor, MD, DMsc</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuminuria</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Butyric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

